Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 4/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690091 | 0.78 | NPC1 (0.38) | TSHRTP53NPC1LMNARAB9A | |
| SCHEMBL690010 | 0.75 | TSHR (0.31) | TSHRTP53NPC1LMNARAB9A | |
| SCHEMBL1032918 | 0.75 | TSHR (0.32) | TSHRTP53NPC1LMNARAB9A | |
| Hydrochloric Acid SCHEMBL688913 | 0.74 | TSHR (0.30) | TSHRTP53NPC1LMNARAB9A | |
| SCHEMBL690009 | 0.74 | NPC1 (0.33) | TSHRTP53NPC1LMNARAB9A | |
| SCHEMBL688912 | 0.72 | NPC1 (0.31) | TP53NPC1LMNARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1030540 | 0.70 | KIF11 (0.31) | KIF11 | |
| SCHEMBL6384768 | 0.68 | KDM4E (0.30) | SMN1; SMN2HTT | |
| SCHEMBL21381466 | 0.67 | TSHR (0.40) | TSHRTP53NPC1LMNARAB9A | |
| SCHEMBL690894 | 0.67 | NPC1 (0.31) | TP53NPC1LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168556-B2 | Racemoselective synthesis of ansa-metallocene compounds, ansa-metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2012-05-01 | — | — | US | disclosed |
| US-20100261860-A1 | RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261860-A1 | RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | MAOA, SNCA, ARSA | TSHR 4600/4885TP53 4214/4885NPC1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.